NeoGenomics, Inc. Stock News

NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGenomics missed revenue estimates, causing a 15.50% drop in the stock price. NeoGenomics shows promising long-term growth potential with rising cancer cases and improving ROIC, but negative profitabili...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in several upcoming investor conferences.

NeoGenomics, Inc (NASDAQ:NEO ) Q4 2024 Earnings Conference Call February 18, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Executive Officer Warren Stone - Chief Commercial Officer Andrew Lukowiak - Chief Innovation Officer Jeffrey Sherman - Chief Financial Officer Kareem Saad - Head, Strategy and Transformation Nate Montgom...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full year results for the period ended December 31, 2024.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Feb. 18, 2025.

NeoGenomics stock jumped Wednesday after the company issued a strong 2025 outlook. That partially reversed a recent selloff.

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan.

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' Chris Smith will retire as CEO and board member, effective April 1, 2025. Tony Zook will assume the role of CEO at that time.